Browsing by Author Oliveira, Mafalda

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)
19-Mar-2021Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancerGriguolo, Gaia; Serna, G.; Pascual, Tomás; Fasani, R.; Guardia, X.; Chic, Núria; Paré, Laia; Pernas, Sònia; Muñoz Mateu, Montserrat; Oliveira, Mafalda; Vidal, M.; Llombart Cussac, Antonio; Cortés, Javier; Galván, Patricia; Bermejo de las Heras, Begoña; Martínez, N.; López, R.; Morales, Serafín; Garau, Isabel; Manso, Luis; Alarcón, Jesús; Martínez, E.; Villagrasa, Patricia; Prat Aparicio, Aleix; Nuciforo, Paolo
20-Jan-2020Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockadeBrasó Maristany, Fara; Griguolo, Gaia; Pascual, Tomás; Paré, Laia; Nuciforo, Paolo; Llombart Cussac, Antonio; Bermejo de las Heras, Begoña; Oliveira, Mafalda; Morales, Serafín; Martínez, Noelia; Vidal Losada, Maria Jesús; Adamo, Barbara; Martínez, Olga; Pernas, Sònia; López, Rafael; Muñoz Mateu, Montserrat; Chic, Núria; Galván, Patricia; Garau, Isabel; Manso, Luis; Alarcón, Jesús; Martínez, Eduardo; Gregorio, Sara; Gomis, Roger R.; Villagrasa, Patricia; Cortés, Javier; Ciruelos, Eva; Prat Aparicio, Aleix
9-Jan-2019Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trialGavilá, Joaquín; Oliveira, Mafalda; Pascual, Tomás; Perez-Garcia, Jose; Gonzàlez, Xavier; Canes, Jordi; Paré Brunet, Laia; Calvo, Isabel; Ciruelos, Eva; Muñoz Mateu, Montserrat; Virizuela, Juan A.; Ruiz, Isabel; Andrés, Raquel; Perelló, Antonia; Martínez, Jerónimo; Morales, Serafín; Marín Aguilera, Mercedes; Martínez, Debora; Quero, Juan C.; Llombart-Cussac, Antonio; Prat Aparicio, Aleix
23-Apr-2021SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast CancerPascual, Tomás; Oliveira, Mafalda; Ciruelos, Eva; Bellet Ezquerra, Meritxell; Saura, Cristina; Gavilá, Joaquin; Pernas, Sònia; Muñoz, Montserrat; Vidal, Maria J.; Margelí Vila, Mireia; Cejalvo Andújar, Juan Miguel; González Farré, Blanca; Espinosa Bravo, Martin; Cruz, Josefina; Salvador Bofill, Francisco Javier; Guerra, Juan Antonio; Luna Barrera, Ana María; Arumi de Dios, Miriam; Esker, Stephen; Fan, Pang-dian; Martínez Sáez, Olga; Villacampa, Guillermo; Paré, Laia; Ferrero Cafiero, Juan M.; Villagrasa, Patricia; Prat Aparicio, Aleix